FUTURE OF HEALTHCARE
CareView Communications, Inc. | November 17, 2022
CareView Communications, Inc. an information technology provider to the healthcare industry, announced the signing of an agreement with a health system building a new campus in Pensacola, FL. The new campus includes a new acute care hospital and behavioral health unit with room for future expansion.
The agreement calls for the installation of the CareView Patient Safety System®, which facilitates continuous remote patient monitoring for patients who may be at risk of harm due to falls, behavioral issues, or suicidal ideation. The CareView solution leverages an in-room camera with audio capabilities and patented Virtual Bed Rails® and Virtual Chair Rails® technologies to improve patient safety. The Virtual Rails use machine learning to identify when the patient's movement indicates a fall may be imminent, and subsequently alerts the Safety Technician. Pre-recorded messages or 2-way audio allow for direct communication with the patient. The System offers a considerable impact on sitter reduction and overall patient safety.
“We are pleased to be working with our newest partner and know that our System is the solution to address their needs to reduce patient falls and increase patient safety.”
Sandra McRee, CareView’s Chief Operating Officer
About CareView Communications, Inc.
As a leader in turnkey patient video monitoring solutions, CareView is redefining the standard of patient safety in hospitals and healthcare facilities across the country. For over a decade, CareView has relentlessly pursued innovative ways to increase patient protection, providing next-generation solutions that lower operational costs and foster a culture of safety among patients, staff, and hospital leadership. With installations in more than 150 hospitals, CareView has proven that its innovative technology is creating a culture of patient safety where patient falls have decreased by 80% with sitter costs reduced by more than 65%. Anchored by the CareView Patient Safety System, this modular, scalable solution delivers flexible configurations to fit any facility while significantly increasing patient safety and operational savings. All configurations feature HD cameras, high-fidelity 2-way audio/video, LCD displays for the ultimate in capability, flexibility, and affordability. Corporate offices are located at 405 State Highway 121 Bypass, Suite B-240, Lewisville, TX 75067.
FUTURE OF HEALTHCARE
Medcase | November 29, 2022
Medcase, a leading solution provider for healthcare AI, and NTT DATA, a digital business and IT services leader, have signed a definitive agreement to enable data discovery and enrichment solutions for healthcare imaging.
AI in healthcare is beginning to demonstrate an ability to improve productivity and outcomes in a competitive market space. Fulfilling data needs and enriching image data sets with annotation and labeling confronts an industry focused on critical development and release timelines. The new partnership between Medcase and NTT DATA addresses that inefficiency allowing AI developers and life sciences to focus on their training and data science.
“Enabling access to rich medical datasets has become paramount to our customers focused on reducing the time from concept to algorithm production. Partnering with NTT DATA is exciting for us as we can now assist innovators with access to curated data, coupled with our enrichment solutions powered by Medcase’s global network of health care professionals and annotators from radiologists to gastroenterologists working side by side with AI developers.”
Kyle Giddens, CEO and Co-Founder of Medcase
The collaboration will enable innovators working with Medcase to access enriched patient studies, including medical imaging, through NTT DATA’s Advocate AI data cooperative network. Medcase’s curation services and AI annotation solutions leverage a global network of healthcare experts to identify, diagnose, and audit medical data according to annotation and labeling guidelines from research, all the way to FDA reader studies.
“Data diversity across technology and patient populations is fundamental to ensuring strong analytics’ training and high conformance,” said Mitchell Goldburgh, Senior Director, Enterprise Imaging and Analytics, NTT DATA Services. “Confidence in AI grows by having a dynamic and broadly trained team of annotators complementing the data with their diversity in the art of annotation. We are pleased to have been chosen by Medcase as a go-to-market partner in advocating the adoption of AI.”
“Advancing technology innovation in the digital and medical space is the best way to improve patient outcomes quickly,” said Giddens. “This is why we are excited to partner with NTT DATA to accelerate AI to the market with essential data annotation, labeling, and enablement that they need to innovate. Access to health care professionals should be as easy as spinning up a new cloud instance on Amazon, we make that easy with our platform and API’s.”
About NTT DATA
NTT DATA is a $30 billion trusted global innovator of IT and business services. We help clients transform through business and technology consulting, industry and digital solutions, applications development, and managed edge-to-cloud infrastructure services, BPO, systems integration, and global data centers. We are committed to our client's long-term success and combine global reach with local client service in over 80 countries.
Medcase is changing how businesses access medical expertise, knowledge, and data by building the largest global network of on-demand healthcare professionals working remotely to assist healthcare innovators and AI developers.
By empowering leading industry leaders in medical devices, AI, and technology companies to pharmaceuticals and telemedicine, Medcase helps accelerate healthcare innovation and bring new medical technologies to market by connecting them to experts to enrich medical data, surveys, or interviews to assess go-to-market and regulation and even providing staffing for valuable telehealth or remote patient monitoring services.
FUTURE OF HEALTHCARE
BIOINTELLISENSE | November 15, 2022
BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company, today announced its partnership with the Translational Research Institute for Space Health (TRISH) to further understanding of human health in space. The BioButton® medical grade wearable device will be used for commercial spaceflight research programs and notably during the upcoming five-day Polaris Dawn mission. This historic mission will be flown by SpaceX and is scheduled to launch after March 2023. Medical and scientific research on human health in space promotes the advancement of translational technologies by adapting known technology for space applications, and by using space-based insights to improve healthcare at home.
“BioIntelliSense has proudly gained industry recognition for its innovative and comprehensive portfolio of continuous multi-parameter monitoring solutions for application in the acute care environment, at home settings and now, in the next frontier of space, As a lifelong space exploration enthusiast, it is a tremendous honor to be working with TRISH on health research that can benefit astronauts and crews during commercial space flight and for the BioButton devices to be part of the upcoming Polaris Dawn mission.”
-James Mault, MD, founder and CEO of BioIntelliSense
The BioButton multi-parameter device is designed to be worn on the upper left chest and will passively capture trending physiologic and movement data from the Polaris Dawn crew during its milestone mission. The future of healthcare is here. Today, the BioIntelliSense Data-as-a-Service (DaaS) platform and clinical intelligence solution is commercially available and rapidly adopted by acute and post-acute providers in the U.S. along with select international markets.
TRISH is proud to partner with innovative healthcare technology leaders like BioIntelliSense as we further our understanding of human health in space, Our EXPAND (Enhancing eXploration and ANalog Definition) commercial spaceflight health research platform provides unique opportunities to rapidly test technologies in orbit, as well as collect new datapoints on the health impact of spaceflight for a wider, more diverse population,said James Hury, TRISH Chief Innovation Officer and Deputy Director.
BioIntelliSense (Booth #5025) and TRISH (Space Health Pavilion #2636) will be showcasing the BioButton wearable device and clinical intelligence solution at the premier HLTH 2022 conference November 13 – 16 in Las Vegas, NV.
BioIntelliSense is ushering in a new era of continuous health monitoring and clinical intelligence for remote patient monitoring (RPM). Its medical-grade Data-as-a-Service (DaaS) platform seamlessly captures multi-parameter vital signs, physiological biometrics and symptomatic events through an effortless patient experience. The medical-grade BioButton® wearable device makes remote monitoring and early detection simple. Through the platform’s advanced analytics, clinicians have access to high-resolution patient trending and reporting to enable medical grade remote care from in-hospital to home.
ABOUT TRANSLATIONAL RESEARCH INSTITUTE for SPACE HEALTH (TRISH)
Led by Baylor College of Medicine’s Center for Space Medicine, TRISH is a consortium that includes partners Caltech and MIT. NASA recently awarded the Institute a six-year extension to further its work by delivering disruptive solutions to mitigate biomedical risks for human exploration while advancing terrestrial health technologies.